UK markets closed

Compass Therapeutics, Inc. (CMPX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.1000-0.0100 (-0.90%)
At close: 04:00PM EDT
1.1100 +0.01 (+0.91%)
After hours: 05:25PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 152.04M
Enterprise value -2.81M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.97
Enterprise value/revenue N/A
Enterprise value/EBITDA -8.92

Trading information

Stock price history

Beta (5Y monthly) 0.71
52-week change 3-65.41%
S&P500 52-week change 326.24%
52-week high 33.3100
52-week low 31.0600
50-day moving average 31.4534
200-day moving average 31.6935

Share statistics

Avg vol (3-month) 3310.43k
Avg vol (10-day) 3450.83k
Shares outstanding 5137.59M
Implied shares outstanding 6137.59M
Float 898.07M
% held by insiders 112.04%
% held by institutions 170.88%
Shares short (15 May 2024) 41.64M
Short ratio (15 May 2024) 46.2
Short % of float (15 May 2024) 41.68%
Short % of shares outstanding (15 May 2024) 41.19%
Shares short (prior month 15 Apr 2024) 41.62M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-19.13%
Return on equity (ttm)-27.35%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -52.76M
Net income avi to common (ttm)-45.44M
Diluted EPS (ttm)-0.3500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)156.26M
Total cash per share (mrq)1.14
Total debt (mrq)1.41M
Total debt/equity (mrq)0.90%
Current ratio (mrq)40.74
Book value per share (mrq)1.14

Cash flow statement

Operating cash flow (ttm)-42.28M
Levered free cash flow (ttm)-26.01M